Rankings
▼
Calendar
MESO FY 2020 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena
MESO
Mesoblast Limited
$2B
FY 2020 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$32M
+92.3% YoY
Gross Profit
-$49M
-153.4% margin
Operating Income
-$75M
-232.8% margin
Net Income
-$78M
-242.4% margin
EPS (Diluted)
$-1.50
Cash Flow
Operating Cash Flow
-$56M
Free Cash Flow
-$59M
Stock-Based Comp.
$8M
Balance Sheet
Total Assets
$734M
Total Liabilities
$184M
Stockholders' Equity
$549M
Cash & Equivalents
$129M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$32M
$17M
+92.3%
Gross Profit
-$49M
-$58M
+15.6%
Operating Income
-$75M
-$80M
+6.6%
Net Income
-$78M
-$90M
+13.2%
← Q4 2019
All Quarters
Q1 2020 →